Correlation of Pattern of Spread and Outcomes in Advanced Epithelial Ovarian Cancers
- PMID: 29887688
- PMCID: PMC5984838
- DOI: 10.1007/s13193-017-0618-5
Correlation of Pattern of Spread and Outcomes in Advanced Epithelial Ovarian Cancers
Abstract
The purpose of this study was to correlate the pattern of spread with oncological outcomes in advanced ovarian cancer patients. This is a retrospective analysis of 55 consecutive patients who had advanced epithelial ovarian cancer or primary peritoneal carcinomatosis (stages 3C and 4) with primary surgical intervention as the initial modality of treatment. Based on the spread of disease, they were further classified into class A: disease confined to the pelvis (excluded); class B: disease extending to the lower abdomen and omentum; class C: diffuse small-bowel disease with or without A, B, or D; and class D: disease in the upper abdomen. There were 17 patients (30.9%) in class B, 17 (30.9%) in class C, and 21 (38.2%) in class D. The number of patients with suboptimal cytoreduction was highest in class C (six patients). At the end of follow-up (median 38.6 months), 16 patients had no evidence of disease and 26 patients were alive with disease. The 3-year overall survival rates in classes B, C, and D were 94.1, 52.5, and 93.3%, respectively. The 3-year progression-free survival rates were 55.8, 11.8, and 41.9%, respectively. The rates were lowest for class C. The differences in the overall survival rate (p < 0.001) and progression-free survival rate (p = 0.001) were statistically significant. In advanced ovarian cancer patients, the presence of disease in the small-bowel serosa and mesentery results in poorer outcomes in terms of overall and progression-free survival. The number of patients with suboptimal cytoreduction was also highest in this group.
Keywords: Advanced ovarian cancer; Epithelial ovarian cancers; Optimal cytoreduction; Pattern of spread; Survival.
Conflict of interest statement
Compliance with Ethical StandardsNone
Figures



Similar articles
-
Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome.Eur J Cancer. 2012 Mar;48(5):687-94. doi: 10.1016/j.ejca.2011.06.034. Epub 2011 Jul 13. Eur J Cancer. 2012. PMID: 21757333
-
The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.Gynecol Oncol. 2008 Feb;108(2):287-92. doi: 10.1016/j.ygyno.2007.10.001. Epub 2007 Nov 13. Gynecol Oncol. 2008. PMID: 17996927
-
Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.Minerva Ginecol. 2017 Apr;69(2):119-127. doi: 10.23736/S0026-4784.16.03959-9. Epub 2016 Jul 14. Minerva Ginecol. 2017. PMID: 27415829
-
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.Gynecol Oncol. 2006 Dec;103(3):1083-90. doi: 10.1016/j.ygyno.2006.06.028. Epub 2006 Aug 4. Gynecol Oncol. 2006. PMID: 16890277
-
Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer.Eur J Surg Oncol. 2011 Jan;37(1):4-9. doi: 10.1016/j.ejso.2010.11.004. Epub 2010 Nov 26. Eur J Surg Oncol. 2011. PMID: 21112721 Review.
Cited by
-
Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients.Indian J Surg Oncol. 2021 Jun;12(2):258-265. doi: 10.1007/s13193-021-01304-w. Epub 2021 Mar 3. Indian J Surg Oncol. 2021. PMID: 34295068 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;1(5):136. - PubMed
-
- Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–S192. doi: 10.1016/S0020-7292(06)60033-7. - DOI - PubMed
-
- Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103(2):559–564. doi: 10.1016/j.ygyno.2006.03.051. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources